Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc (INO) Covered Calls
As of September 25, 2026, INO has 15 covered call opportunities in the coming three months. Return ranges from 32.0 to 304.0% until expiration. Annualized return ranges from 18.9 to 906.2%. The nearest expiration is November 20, 2026. Maximum potential profit is $380.
Read more
Running INO covered calls helps you generate consistent income from Inovio Pharmaceuticals Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Inovio Pharmaceuticals Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best INO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if INO stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling INO covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Inovio Pharmaceuticals Inc covered call is worth writing.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.
Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Income-focused investors, long-term INO holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling INO covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Inovio Pharmaceuticals Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile90.48% Elevated
- Market cap (M$)122
- 52 weeks high-56.62%
- 52 weeks low110.71%
- Analyst recommendationBuy
1.67 - Target price$3.17
168.64% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-1.18
- EPS growth next 5 years61.91%
As of September 25, 2026
| 2026-11-20 | 58 | 3.00 | 140.00 | 0.05 | 0.50 | 180.00 | 144.00 | 906.21 | -4.00 | +0.44 | 5,503 | 0.45 |
| 2026-11-20 | 58 | 2.00 | 60.00 | 0.15 | 0.30 | 90.00 | 72.00 | 453.10 | -12.00 | +0.44 | 3,045 | 0.15 |
| 2027-02-19 | 149 | 3.00 | 140.00 | 0.10 | 3.50 | 185.00 | 148.00 | 362.55 | -8.00 | +1.00 | 10 | 3.40 |
| 2026-12-18 | 86 | 2.00 | 60.00 | 0.20 | 0.25 | 95.00 | 76.00 | 322.56 | -16.00 | +0.44 | 4,921 | 0.05 |
| 2027-01-15 | 114 | 2.00 | 60.00 | 0.15 | 0.40 | 90.00 | 72.00 | 230.53 | -12.00 | +0.49 | 3,624 | 0.25 |
| 2028-01-21 | 485 | 5.00 | 300.00 | 0.05 | 1.00 | 380.00 | 304.00 | 228.78 | -4.00 | +0.61 | 672 | 0.95 |
| 2026-11-20 | 58 | 1.50 | 20.00 | 0.20 | 0.45 | 45.00 | 36.00 | 226.55 | -16.00 | +0.58 | 1,658 | 0.25 |
| 2028-01-21 | 485 | 4.00 | 220.00 | 0.10 | 0.65 | 285.00 | 228.00 | 171.59 | -8.00 | +0.51 | 71 | 0.55 |
| 2026-12-18 | 86 | 1.50 | 20.00 | 0.20 | 0.45 | 45.00 | 36.00 | 152.79 | -16.00 | +0.58 | 1,264 | 0.25 |
| 2027-01-15 | 114 | 1.50 | 20.00 | 0.20 | 0.45 | 45.00 | 36.00 | 115.26 | -16.00 | +0.58 | 24,848 | 0.25 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best INO covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→